Prognostic significance of plasma resistin levels in patients with atherothrombotic ischemic stroke

Clinica Chimica Acta

Volumn 378, Issue 1-2, 2007, Pages 78-85

  Efstathiou, Stamatis P ^a   Tsiakou, Aphrodite G ^b   Tsioulos, Dimitrios I ^b   Panagiotou, Themistoklis N ^b   Pefanis, Angelos V ^b   Achimastos, Apostolos D ^b   Mountokalakis, Theodore D ^a  

^a Department of Pathology   (Greece)

^b Third University   (Greece)

Author keywords

Functional outcome; Ischemic stroke; Prognosis; Resistin; Survival

Indexed keywords

C REACTIVE PROTEIN; RESISTIN;

AGE; AGED; ARTICLE; ATHEROTHROMBOTIC ISCHEMIC STROKE; CEREBROVASCULAR ACCIDENT; CONFIDENCE INTERVAL; CONTROLLED STUDY; DEATH; FEMALE; HAZARD RATIO; HUMAN; ISCHEMIC HEART DISEASE; KAPLAN MEIER METHOD; MAJOR CLINICAL STUDY; MALE; MORTALITY; NATIONAL INSTITUTES OF HEALTH STROKE SCALE; OUTCOME ASSESSMENT; PREDICTOR VARIABLE; PRIORITY JOURNAL; PROBABILITY; PROGNOSIS; PROPORTIONAL HAZARDS MODEL; RANKIN SCALE; RISK ASSESSMENT; SURVIVAL;

ADULT; AGED; ATHEROSCLEROSIS; BRAIN ISCHEMIA; CEREBROVASCULAR ACCIDENT; FEMALE; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PROGNOSIS; RESISTIN;

EID: 33846955408     PISSN: 00098981     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cca.2006.10.023     Document Type: Article

References (58)

1. McTernan P.G., Kusminski C.M., and Kumar S. Resistin. Curr Opin Lipidol 17 (2006) 170-175
2. Steppan C.M., Bailey S.T., Bhat S., et al. The hormone resistin links obesity to diabetes. Nature 409 (2001) 307-312
3. Banerjee R.R., Rangwala S.M., Shapiro J.S., et al. Regulation of fasted blood glucose by resistin. Science 303 (2004) 1195-1198
4. McTernan C.L., McTernan P.G., Harte A.L., Levick P.L., Barnett A.H., and Kumar S. Resistin, central obesity, and type 2 diabetes. Lancet 359 (2002) 46-47
5. Azuma K., Katsukawa F., Oguchi S., et al. Correlation between serum resistin level and adiposity in obese individuals. Obes Res 11 (2003) 997-1001
6. Degawa-Yamauchi M., Bovenkerk J.E., Juliar B.E., et al. Serum resistin (FIZZ3) protein is increased in obese humans. J Clin Endocrinol Metab 88 (2003) 5452-5455
7. Conneely K.N., Silander K., Scott L.J., et al. Variation in the resistin gene is associated with obesity and insulin-related phenotypes in Finnish subjects. Diabetologia 47 (2004) 1782-1788
8. Vozarova de Courten B., Degawa-Yamauchi M., Considine R.V., and Tataranni P.A. High serum resistin is associated with an increase in adiposity but not a worsening of insulin resistance in Pima Indians. Diabetes 53 (2004) 1279-1284
9. Vilarrasa N., Vendrell J., Maravall J., et al. Distribution and determinants of adiponectin, resistin and ghrelin in a randomly selected healthy population. Clin Endocrinol (Oxf) 63 (2005) 329-335
10. Wang H., Chu W.S., Hemphill C., and Elbein S.C. Human resistin gene: molecular scanning and evaluation of association with insulin sensitivity and type 2 diabetes in Caucasians. J Clin Endocrinol Metab 87 (2002) 2520-2524
11. Zhang J.L., Qin Y.W., Zheng X., Qiu J.L., and Zou D.J. Serum resistin level in essential hypertension patients with different glucose tolerance. Diabet Med 20 (2003) 828-831
12. Silha J.V., Krsek M., Skrha J.V., Sucharda P., Nyomba B.L., and Murphy L.J. Plasma resistin, adiponectin and leptin levels in lean and obese subjects: correlations with insulin resistance. Eur J Endocrinol 149 (2003) 331-335
13. Chu M.C., Cosper P., Orio F., Carmina E., and Lobo R.A. Insulin resistance in postmenopausal women with metabolic syndrome and the measurements of adiponectin, leptin, resistin, and ghrelin. Am J Obstet Gynecol 194 (2006) 100-104
14. Burnett M.S., Devaney J.M., Adenika R.J., Lindsay R., and Howard B.V. Cross-sectional associations of resistin, coronary heart disease, and insulin resistance. J Clin Endocrinol Metab 91 (2006) 64-68
15. Fujinami A., Obayashi H., Ohta K., et al. Enzyme-linked immunosorbent assay for circulating human resistin: resistin concentrations in normal subjects and patients with type 2 diabetes. Clin Chim Acta 339 (2004) 57-63
16. Youn B.S., Yu K.Y., Park H.J., et al. Plasma resistin concentrations measured by enzyme-linked immunosorbent assay using a newly developed monoclonal antibody are elevated in individuals with type 2 diabetes mellitus. J Clin Endocrinol Metab 89 (2004) 150-156
17. Lee J.H., Chan J.L., Yiannakouris N., et al. Circulating resistin levels are not associated with obesity or insulin resistance in humans and are not regulated by fasting or leptin administration: cross-sectional and interventional studies in normal, insulin-resistant, and diabetic subjects. J Clin Endocrinol Metab 88 (2003) 4848-4856
18. Heilbronn L.K., Rood J., Janderova L., et al. Relationship between serum resistin concentrations and insulin resistance in nonobese, obese, and obese diabetic subjects. J Clin Endocrinol Metab 89 (2004) 1844-1848
19. Shetty G.K., Economides P.A., Horton E.S., Mantzoros C.S., and Veves A. Circulating adiponectin and resistin levels in relation to metabolic factors, inflammatory markers, and vascular reactivity in diabetic patients and subjects at risk for diabetes. Diabetes Care 27 (2004) 2450-2457
20. Chen C.C., Li T.C., Li C.I., Liu C.S., Wang H.J., and Lin C.C. Serum resistin level among healthy subjects: relationship to anthropometric and metabolic parameters. Metabolism 54 (2005) 471-475
21. Hasegawa G., Ohta M., Ichida Y., et al. Increased serum resistin levels in patients with type 2 diabetes are not linked with markers of insulin resistance and adiposity. Acta Diabetol 42 (2005) 104-109
22. Farvid M.S., Ng T.W., Chan D.C., Barrett P.H., and Watts G.F. Association of adiponectin and resistin with adipose tissue compartments, insulin resistance and dyslipidaemia. Diabetes Obes Metab 7 (2005) 406-413
23. Iqbal N., Seshadri P., Stern L., et al. Serum resistin is not associated with obesity or insulin resistance in humans. Eur Rev Med Pharmacol Sci 9 (2005) 161-165
24. Utzschneider K.M., Carr D.B., Tong J., et al. Resistin is not associated with insulin sensitivity or the metabolic syndrome in humans. Diabetologia 48 (2005) 2330-2333
25. Bo S., Gambino R., Pagani A., et al. Relationships between human serum resistin, inflammatory markers and insulin resistance. Int J Obes Relat Metab Disord 29 (2005) 1315-1320
26. Kunnari A., Ukkola O., Paivansalo M., and Kesaniemi Y.A. High plasma resistin level is associated with enhanced hsCRP and leucocytes. J Clin Endocrinol Metab 91 (2006) 2755-2760
27. Lehrke M., Reilly M.P., Millington S.C., Iqbal N., Rader D.J., and Lazar M.A. An inflammatory cascade leading to hyperresistinemia in humans. PLoS Med 1 (2004) e45
28. Reilly M.P., Lehrke M., Wolfe M.L., Rohatgi A., Lazar M.A., and Rader D.J. Resistin is an inflammatory marker of atherosclerosis in humans. Circulation 111 (2005) 932-939
29. Jung H.S., Park K.H., Cho Y.M., et al. Resistin is secreted from macrophages in atheromas and promotes atherosclerosis. Cardiovasc Res 69 (2006) 76-85
30. Papadopoulos D.P., Makris T.K., Krespi P.G., et al. Adiponectin and resistin plasma levels in healthy individuals with prehypertension. J Clin Hypertens (Greenwich) 7 (2005) 729-733
31. Ohmori R., Momiyama Y., Kato R., et al. Associations between serum resistin levels and insulin resistance, inflammation, and coronary artery disease. J Am Coll Cardiol 46 (2005) 379-380
32. Al-Daghri N., Chetty R., McTernan P.G., et al. Serum resistin is associated with c-reactive protein and ldl cholesterol in type 2 diabetes and coronary artery disease in a Saudi population. Cardiovasc Diabetol 4 (2005) 10
33. Pischon T., Bamberger C.M., Kratzsch J., et al. Association of plasma resistin levels with coronary heart disease in women. Obes Res 13 (2005) 1764-1771
34. Lubos E., Messow C.M., Schnabel R., et al. Resistin, acute coronary syndrome and prognosis results from the AtheroGene study. Atherosclerosis (Jun 27 2006) 10.1016/j.atherosclerosis.2006.05.039
35. Chalela J.A., Merino J.G., and Warach S. Update on stroke. Curr Opin Neurol 17 (2004) 447-451
36. Chamorro A., and Hallenbeck J. The harms and benefits of inflammatory and immune responses in vascular disease. Stroke 37 (2006) 291-293
37. Efstathiou S.P., Tsioulos D.I., Tsiakou A.G., Gratsias Y., Pefanis A., and Mountokalakis T. Plasma adiponectin levels and five-year survival after first-ever ischemic stroke. Stroke 36 (2005) 1915-1919
38. Kunnari A., Ukkola O., and Kesaniemi Y.A. Resistin polymorphisms are associated with cerebrovascular disease in Finnish type 2 diabetic patients. Diabet Med 22 (2005) 583-589
39. Adams Jr. H.P., Bendixen B.H., Kappelle L.J., et al. Classification of subtype of acute ischemic stroke: definitions for use in a multicenter clinical trial. Stroke 24 (1993) 35-41
40. van der Worp H.B., Claus S.P., Bar P.R., et al. Reproducibility of measurements of cerebral infarct volume on CT scans. Stroke 32 (2001) 424-430
41. Brott T., Adams Jr. H.P., Olinger C.P., et al. Measurements of acute cerebral infarction: a clinical examination scale. Stroke 20 (1989) 864-870
42. Sulter G., Steen C., and De Keyser J. Use of the Barthel index and modified Rankin scale in acute stroke trials. Stroke 30 (1999) 1538-1541
43. Di Napoli M., and Papa F. Villa Pini Stroke Data Bank Investigators. Inflammation, hemostatic markers, and antithrombotic agents in relation to long-term risk of new cardiovascular events in first-ever ischemic stroke patients. Stroke 33 (2002) 1763-1771
44. Beamer N.B., Coull B.M., Clark W.M., Briley D.P., Wynn M., and Sexton G. Persistent inflammatory response in stroke survivors. Neurology 50 (1998) 1722-1728
45. Di Napoli M., Papa F., and Bocola V. Prognostic influence of increased C-reactive protein and fibrinogen levels in ischemic stroke. Stroke 32 (2001) 133-138
46. Bassuk S.S., Rifai N., and Riker P.M. High-sensitivity C-reactive protein: clinical importance. Curr Probl Cardiol 29 (2004) 439-493
47. Smith C.J., Emsley H.C., Gavin C.M., et al. Peak plasma interleukin-6 and other peripheral markers of inflammation in the first week of ischaemic stroke correlate with brain infarct volume, stroke severity and long-term outcome. BMC Neurol 4 (2004) 2
48. Ridker P.M., Hennekens C.H., Roitman-Johnson B., Stamfer M.J., and Allen J. Plasma concentration of soluble intercellular adhesion molecule 1 and risks of future myocardial infarction in apparently healthy men. Lancet 351 (1998) 88-92
49. Lindsberg P.J., and Roine R.O. Hyperglycemia in acute stroke. Stroke 35 (2004) 363-364
50. Clark W.M. Adiponectin: spectator or player?. Stroke 36 (2005) 1919-1920
51. Szapary P.O., Bloedon L.T., Samaha F.F., et al. Effects of pioglitazone on lipoproteins, inflammatory markers, and adipokines in nondiabetic patients with metabolic syndrome. Arterioscler Thromb Vasc Biol 26 (2006) 182-188
52. Jung H.S., Youn B.S., Cho Y.M., et al. The effects of rosiglitazone and metformin on the plasma concentrations of resistin in patients with type 2 diabetes mellitus. Metabolism 54 (2005) 314-320
53. Ghanim H., Dhindsa S., Aljada A., Chaudhuri A., Viswanathan P., and Dandona P. Low dose rosiglitazone exerts an anti-inflammatory effect with an increase in adiponectin independently of free fatty acid (FFA) fall and insulin sensitization in obese type 2 diabetics. J Clin Endocrinol Metab 91 (2006) 3553-3558
54. Rea R., and Donnelly R. Effects of metformin and oleic acid on adipocyte expression of resistin. Diabetes Obes Metab 8 (2006) 105-109
55. Rasouli N., Yao-Borengasser A., Miles L.M., Elbein S.C., and Kern P.A. Increased plasma adiponectin in response to pioglitazone does not result from increased gene expression. Am J Physiol Endocrinol Metab 290 (2006) E42-E46
56. Ichida Y., Hasegawa G., Fukui M., et al. Effect of atorvastatin on in vitro expression of resistin in adipocytes and monocytes/macrophages and effect of atorvastatin treatment on serum resistin levels in patients with type 2 diabetes. Pharmacology 76 (2006) 34-39
57. Yin W.H., Jen H.L., Chen J.W., Lin S.J., and Young M.S. Differential effects of peroxisome proliferator-activated receptor ligands and sulfonylurea plus statin treatment on plasma concentrations of adipokines in type 2 diabetes with dyslipidemia. Diabetes Metab 32 (2006) 229-235
58. Chu C.S., Lee K.T., Lee M.Y., et al. Effects of atorvastatin and atorvastatin withdrawal on soluble CD40L and adipocytokines in patients with hypercholesterolaemia. Acta Cardiol 61 (2006) 263-269